Solomon C, Baryshnikova E, Tripodi A, Schlimp C J, Schöchl H, Cadamuro J, Winstedt D, Asmis L, Ranucci M
Associate Prof. Cristina Solomon, MD, Commercial Development Acquired Bleeding Disorders, CSL Behring GmBH, Emil-von-Behring-Strasse 76, 35041 Marburg, Germany, Tel: +49 6421 39 5813, Fax: +49 6421 39 4146, E-mail:
Thromb Haemost. 2014 Jul 3;112(1):109-17. doi: 10.1160/TH13-12-0997. Epub 2014 Mar 13.
Plasma fibrinogen concentration is important for coagulopathy assessment, and is most commonly measured using the Clauss method. Several factors, including device type and reagent, have been shown to affect results. The study objective was to evaluate performance and repeatability of the Clauss method and to assess differences between measurements performed during and after cardiopulmonary bypass (CPB), by testing plasma samples from patients undergoing cardiac surgery with CPB. Samples were collected from 30 patients before surgery, approximately 20 minutes before weaning from CPB, and 5 minutes after CPB and protamine. Fibrinogen concentration was determined using the Clauss method at six quality-controlled specialised laboratories, according to accredited standard operating procedures. Regarding within-centre agreement for Clauss measurement, mean differences between duplicate measurements were between 0.00 g/l and 0.15 g/l, with intervals for 95% limits of agreement for mean Bland-Altman differences up to 1.3 g/l. Regarding between-centre agreement, some mean differences between pairs of centres were above 0.5 g/l. Differences of up to ~2 g/l were observed with individual samples. Increased variability was observed between centres, with inter-class correlation values below 0.5 suggesting only fair agreement. There were no significant differences in fibrinogen concentration before weaning from CPB and after CPB for most centres and methods. In conclusion, considerable differences exist between Clauss-based plasma fibrinogen measured using different detection methods. Nevertheless, the similarity between measurements shortly before weaning from CPB and after CPB within centres suggests that on-pump measurements could provide an early estimation of fibrinogen deficit after CPB and thus guidance for haemostatic therapy.
血浆纤维蛋白原浓度对于凝血病评估很重要,最常用Clauss法进行测量。包括仪器类型和试剂在内的几个因素已被证明会影响测量结果。本研究的目的是评估Clauss法的性能和重复性,并通过检测接受体外循环(CPB)心脏手术患者的血浆样本,评估CPB期间和之后测量结果的差异。样本采集自30例患者,分别在手术前、CPB撤机前约20分钟、CPB及鱼精蛋白注射后5分钟。根据认可的标准操作程序,在六个质量控制的专业实验室使用Clauss法测定纤维蛋白原浓度。关于Clauss测量的中心内一致性,重复测量之间的平均差异在0.00 g/l至0.15 g/l之间,平均Bland-Altman差异的95%一致性界限区间高达1.3 g/l。关于中心间一致性,部分中心对之间的平均差异超过0.5 g/l。个别样本的差异高达约2 g/l。各中心之间观察到变异性增加,组内相关值低于0.5表明一致性仅为一般。对于大多数中心和方法,CPB撤机前和CPB后的纤维蛋白原浓度没有显著差异。总之,使用不同检测方法基于Clauss法测量的血浆纤维蛋白原之间存在相当大的差异。然而,各中心在CPB撤机前不久和之后测量结果的相似性表明,体外循环期间的测量可以为CPB后纤维蛋白原缺乏提供早期估计,从而为止血治疗提供指导。